Population-Based Epidemiologic Study of Psoriasis With Emphasis on Quality of Life Assessment

Koo, John

doi:10.1016/s0733-8635(05)70376-4

Cited by 340 publications

(302 citation statements)

References 3 publications

Supporting

Mentioning

278

Contrasting

Unclassified

Order By: Relevance

“…When patients need to expose their bodies around swimming pool or public showers, or live under conditions that do not provide appropriate privacy, women may feel ashamed and embarrassed more than men. In another study, patients with psoriasis who reported more severe symptoms were less likely to be married 30 . It is possible that the emotional support associated with having a partner is responsible for the reduced impairment of psoriasis-related QOL.…”

Section: Discussionmentioning

confidence: 94%

Impact of Psoriasis on Quality of Life: Relationship between Clinical Response to Therapy and Change in Health-related Quality of Life

et al. 2010

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 94%

Impact of Psoriasis on Quality of Life: Relationship between Clinical Response to Therapy and Change in Health-related Quality of Life

et al. 2010

View full text Add to dashboard Cite

“…Psoriatic arthritis (PsA) is a chronic inflammatory disorder of the peripheral joints and axial skeleton that occurs in 7-34% of patients with psoriasis (1-4), which, in turn, has a prevalence of 1-3% of the general population (2,5). Many patients have erosive disease, physical limitations, and work-related disability.…”

mentioning

confidence: 99%

Etanercept treatment of psoriatic arthritis: Safety, efficacy, and effect on disease progression

Mease¹,

Kivitz²,

Burch³

et al. 2004

Arthritis & Rheumatism

804

528

View full text Add to dashboard Cite

Objective. Etanercept has been shown to improve the articular and cutaneous manifestations of psoriatic arthritis (PsA). In this study, we further evaluated the safety, efficacy, and effect on radiographic progression of etanercept in patients with PsA.Methods. Patients with PsA (n ‫؍‬ 205) were randomized to receive placebo or 25 mg etanercept subcutaneously twice weekly for 24 weeks. Patients continued to receive blind-labeled therapy in a maintenance phase until all had completed the 24-week phase, then could receive open-label etanercept in a 48-week extension. Efficacy and safety were evaluated at 4, 12, and 24 weeks and at 12-week intervals thereafter. Radiographs of the hands and wrists were assessed at baseline and 24 weeks, at entry to the open-label phase, and after 48 weeks in the study.Results. Etanercept significantly reduced the signs and symptoms of PsA and psoriasis. At 12 weeks, 59% of etanercept patients met the American College of Rheumatology 20% improvement criteria for joint response, compared with 15% of placebo patients (P < 0.0001), and results were sustained at 24 and 48 weeks. At 24 weeks, 23% of etanercept patients eligible for psoriasis evaluation achieved at least 75% improvement in the Psoriasis Area and Severity Index, compared with 3% of placebo patients (P ‫؍‬ 0.001). Radiographic disease progression was inhibited in the etanercept group at 12 months; the mean annualized rate of change in the modified total Sharp score was ؊0.03 unit, compared with ؉1.00 unit in the placebo group (P ‫؍‬ 0.0001). Etanercept was well tolerated.Conclusion. Etanercept reduced joint symptoms, improved psoriatic lesions, inhibited radiographic progression, and was well tolerated in patients with PsA.

show abstract

“…The prevalence of PsA among psoriatic patients ranges from 6% to 48 %, while the prevalence of psoriasis is 1-3% of the population [16][17][18]. In current practice, our result showed that the most frequently clinical findings of PsA were enthesopathy (20.5 %), oligoarthritis (53.8 %), polyarthritis (25.5 %), spondylitis (12.8 %) and DIP involvement (7.71 %).…”

Section: Discussionmentioning

confidence: 99%

Enthesopathy and the Cutaneous Disease Activities in Psoriatic Arthritis

et al. 2013

View full text Add to dashboard Cite

Aim: To investigate entheseal abnormalities by using Leeds Enthesitis Index (LEI) score in Psoriatic arthritis (PsA). Also, to find the correlation of LEI score and parameters of the activities of the cutaneous disease at baseline and after 6 months of treatment in PsA. Furthermore, to find correlation between LEI score and C-reactive protein (CRP) and Psoriasis Area and Severity Index (PASI) score as well as acute phase reactants. Materials and Methods:A total of thirty-nine patients with PsA and thirty-five age and sex matched healthy subjects were recruited. Clinical and laboratory assessment of disease activity included LEI score, PASI score, erythrocyte sedimentation rate (ESR) and CRP and were measured at baseline and after 6 months of treatment.Results: Enthesopathy showed a significant prevalence among PsA of 20.5%. We found a highly significant decreased in LEI score, PASI score, ESR and CRP at baseline compared to results after 6 months of treatment in PsA. A significant correlation between PASI score and LEI score was found. Also, PASI score was significant correlated with ESR and CRP in PsA. Conclusion:Enthesopathy showed a significant prevalence among PsA. The good potential parameters for PsA were LEI score, PASI score, ESR and CRP in PsA. Also, they may be the predictive value of changes induced by biological treatment in PsA.

show abstract

Population-Based Epidemiologic Study of Psoriasis With Emphasis on Quality of Life Assessment

Cited by 340 publications

References 3 publications

Impact of Psoriasis on Quality of Life: Relationship between Clinical Response to Therapy and Change in Health-related Quality of Life

Impact of Psoriasis on Quality of Life: Relationship between Clinical Response to Therapy and Change in Health-related Quality of Life

Etanercept treatment of psoriatic arthritis: Safety, efficacy, and effect on disease progression

Enthesopathy and the Cutaneous Disease Activities in Psoriatic Arthritis

Contact Info

Product

Resources

About